Contact
searchSearch
HMP Global
Login

Ovarian Cancer Resource Center

News
Integrated Clinical Pathway Dashboard Enhances Germline Testing in Patients With Ovarian Cancer
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
News
The Cost-Effectiveness of Prevention Strategies for Individuals Who Carry CSGs for Ovarian Cancer and Breast Cancer
03/18/2024

Grace Taylor

Grace Taylor
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and...
03/18/2024
Journal of Clinical Pathways
News
Individualized Starting Dose of Niraparib in Ovarian Cancer Reduces Hematologic Adverse Event Costs
03/18/2024

Brandon Twyford

Brandon Twyford
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the...
03/18/2024
Journal of Clinical Pathways
News
AI Machine Learning Models Accurately Predict Ovarian Cancer Recurrence and Platinum Sensitivity
03/18/2024
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine...
03/18/2024
Journal of Clinical Pathways
Conference Coverage
Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
From Oncology
News
Safety and Efficacy Analysis of Lurbinectedin in Patients With Advanced Ovarian Tumors
01/16/2024
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by...
01/16/2024
Journal of Clinical Pathways
News
Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer
12/19/2023
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology
From Oncology
Research Reports
Treatment Duration, Adherence, Interruptions, and Discontinuations Associated With Maintenance Regimens for Recurrent Ovarian Cancer
06/05/2023
Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.
Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.
Emma L. Barber, MD, and...
06/05/2023
Journal of Clinical Pathways
News
Minimally Invasive Surgery vs Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy
08/17/2022
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery...
08/17/2022
Journal of Clinical Pathways
News
Anti-mesothelin CAR-T Immunotherapy Could be Effective in Ovarian Cancer
08/16/2022
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
Real-World Management of Mucinous Ovarian Cancer
08/11/2022
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram...
08/11/2022
Journal of Clinical Pathways

Expert Insights

Winston Wong, PharmD
Videos
Pathways Disruptors in Ovarian Cancer
06/22/2022
Winston Wong, PharmD, discusses the ATHENA-MONO trial, an international, randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib as first-line maintenance treatment across a diverse patient population with newly...
Winston Wong, PharmD, discusses the ATHENA-MONO trial, an international, randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib as first-line maintenance treatment across a diverse patient population with newly...
Winston Wong, PharmD, discusses...
06/22/2022
Journal of Clinical Pathways
Eloise Chapman-Davis, MD
Videos
Identifying Disparities in Genetic Testing Among Patients With Ovarian Cancer
06/14/2022
Eloise Chapman-Davis, MD, discusses her research on existing disparities in genetic counseling in ovarian cancer, finding that less than half of patients with newly diagnosed breast or ovarian cancer receive germline testing, despite NCCN...
Eloise Chapman-Davis, MD, discusses her research on existing disparities in genetic counseling in ovarian cancer, finding that less than half of patients with newly diagnosed breast or ovarian cancer receive germline testing, despite NCCN...
Eloise Chapman-Davis, MD,...
06/14/2022
Journal of Clinical Pathways
Jinan Liu, MD, PhD, GlaxoSmithKline
Videos
Real-World Study on Niraparib as First Line Maintenance for Newly Diagnosed Advanced Ovarian Cancer
05/03/2022
Jinan Liu, MD, PhD, evaluated dose assignment and uptake of the individualized starting dose among US patients with ovarian cancer who were receiving niraparib as first-line maintenance therapy, using real-world data.
Jinan Liu, MD, PhD, evaluated dose assignment and uptake of the individualized starting dose among US patients with ovarian cancer who were receiving niraparib as first-line maintenance therapy, using real-world data.
Jinan Liu, MD, PhD, evaluated...
05/03/2022
Journal of Clinical Pathways
Jinan Liu, MD, PhD
Videos
Real-World Use of PARP Inhibitor for First-line Maintenance in Newly Diagnosed Ovarian Cancer
05/02/2022
Jinan Liu, MD, PhD describes the use of first-line maintenance therapies among patients with ovarian cancer and examines predictors of first-line poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor maintenance therapy use.
Jinan Liu, MD, PhD describes the use of first-line maintenance therapies among patients with ovarian cancer and examines predictors of first-line poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor maintenance therapy use.
Jinan Liu, MD, PhD describes the...
05/02/2022
Journal of Clinical Pathways
Sarah Temkin, MD
Videos
Survey Aims to Inform Quality Improvement Initiatives in Ovarian Cancer Care Programs
11/01/2021
Sarah Temkin, MD, discusses a national survey of ovarian cancer care programs in the United States, identifying the needs of patients and informing quality improvement initiatives for these programs.
Sarah Temkin, MD, discusses a national survey of ovarian cancer care programs in the United States, identifying the needs of patients and informing quality improvement initiatives for these programs.
Sarah Temkin, MD, discusses a...
11/01/2021
Journal of Clinical Pathways
Jinan Liu, MD, PhD
Videos
Real-World Maintenance Therapy Use in Newly Diagnosed Ovarian Cancer
07/24/2021
Jinan Liu, MD, discusses results from a real-world study exploring patterns and predictors of maintenance therapy use among patients with newly diagnosed ovarian cancer.
Jinan Liu, MD, discusses results from a real-world study exploring patterns and predictors of maintenance therapy use among patients with newly diagnosed ovarian cancer.
Jinan Liu, MD, discusses results...
07/24/2021
Journal of Clinical Pathways
Katrine Wallace, PhD, MS
Videos
Real-World Utilization of Second-Line Maintenance Therapy for Advanced Ovarian Cancer
07/19/2021
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS,...
07/19/2021
Journal of Clinical Pathways
Videos
Rucaparib vs Chemotherapy for Platinum-Sensitive Patients With Advanced Ovarian Cancer
06/23/2021
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses...
06/23/2021
Journal of Clinical Pathways
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
Videos
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
04/27/2021
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS,...
04/27/2021
Journal of Clinical Pathways
Maintenance Olaparib Demonstrates Long-Term Benefit in BRCA-Mutated Ovarian Cancer
Videos
Maintenance Olaparib Demonstrates Long-Term Benefit in BRCA-Mutated Ovarian Cancer
04/21/2021
04/21/2021
Journal of Clinical Pathways
Sawsan Rashdan, MD
Videos
Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies
11/14/2024
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate...
11/14/2024
Journal of Clinical Pathways
Videos
Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up
11/08/2024
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a...
11/08/2024
Journal of Clinical Pathways
BDHC Thumbnail
Breaking Down Health Care
Navigating Payer Challenges in Cell and Gene Therapy
11/07/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health...
11/07/2024
Cancer Care Business Exchange
Videos
Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
Interview
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
10/30/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
10/30/2024
Journal of Clinical Pathways
JB
Interview
The Road Ahead for CLL Research and Treatment: Overcoming Challenges and Embracing Innovations in Patient Care
10/25/2024
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements...
10/25/2024
Journal of Clinical Pathways
Jessica Paulus, ScD
Interview
Insights on Lung Cancer Diagnosis Trends and Screening Challenges in Community Oncology
10/23/2024
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica...
10/23/2024
Journal of Clinical Pathways
Federico Cappuzzo, MD, National Cancer Institute Regina Elena
Videos
The Impact of Subcutaneous Formulation of Atezolizumab on Treatment for Patients with Non-Small Cell Lung Cancer
10/17/2024
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses...
10/17/2024
Oncology

Newsfeed

News
Integrated Clinical Pathway Dashboard Enhances Germline Testing in Patients With Ovarian Cancer
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
News
The Cost-Effectiveness of Prevention Strategies for Individuals Who Carry CSGs for Ovarian Cancer and Breast Cancer
03/18/2024

Grace Taylor

Grace Taylor
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and...
03/18/2024
Journal of Clinical Pathways
News
Individualized Starting Dose of Niraparib in Ovarian Cancer Reduces Hematologic Adverse Event Costs
03/18/2024

Brandon Twyford

Brandon Twyford
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the...
03/18/2024
Journal of Clinical Pathways
News
AI Machine Learning Models Accurately Predict Ovarian Cancer Recurrence and Platinum Sensitivity
03/18/2024
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine...
03/18/2024
Journal of Clinical Pathways
Conference Coverage
Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
News
Safety and Efficacy Analysis of Lurbinectedin in Patients With Advanced Ovarian Tumors
01/16/2024
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by...
01/16/2024
Journal of Clinical Pathways
News
Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer
12/19/2023
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology
News
Minimally Invasive Surgery vs Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy
08/17/2022
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery...
08/17/2022
Journal of Clinical Pathways
News
Anti-mesothelin CAR-T Immunotherapy Could be Effective in Ovarian Cancer
08/16/2022
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
Real-World Management of Mucinous Ovarian Cancer
08/11/2022
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram...
08/11/2022
Journal of Clinical Pathways
News
Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
Under 50% of Oncology Practices Offer Survivorship Clinics
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
News
Advancing Personalized Treatment in Endometrial Cancer With the HECTOR Deep Learning Model
11/06/2024
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
News
Influence of Socioeconomic and Demographic Factors on Myelofibrosis Outcomes
10/30/2024
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic...
10/30/2024
Journal of Clinical Pathways
News
Hypertension and Endometrial Cancer Risk: A Systematic Review and Meta-Analysis
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways
News
Harnessing the Potential of Abemaciclib in Recurrent Endometrial Cancer Treatment
10/25/2024
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor...
10/25/2024
Journal of Clinical Pathways
News
Pembrolizumab Plus Adjuvant Chemotherapy for Newly Diagnosed High-Risk dMMR Endometrial Cancer
10/21/2024
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with...
10/21/2024
Journal of Clinical Pathways
News
False Negatives More Prevalent in Endometrial Cancer Screening for Black Women
10/17/2024
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA...
10/17/2024
Journal of Clinical Pathways
News
Efficacy of Momelotinib in Managing Anemia in Myelofibrosis: Results from the SIMPLIFY-2 Trial
10/16/2024
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in...
10/16/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Opportunistic Salpingectomy for Ovarian Cancer Prevention
02/24/2022
True or False: Opportunistic salpingectomy at the time of elective cholecystectomy is not a cost-effective strategy to prevent ovarian cancer among average risk women.
True or False: Opportunistic salpingectomy at the time of elective cholecystectomy is not a cost-effective strategy to prevent ovarian cancer among average risk women.
True or False: Opportunistic...
02/24/2022
Journal of Clinical Pathways
Quiz
Quiz: PARP Inhibitors in Patients With Epithelial Ovarian Cancer
12/14/2021
True or False: Findings from a study assessing patients’ and oncologists’ preferences for second-line PARP inhibitor maintenance in epithelial ovarian cancer suggest that the PFS gains are worth the toxicity risk.
True or False: Findings from a study assessing patients’ and oncologists’ preferences for second-line PARP inhibitor maintenance in epithelial ovarian cancer suggest that the PFS gains are worth the toxicity risk.
True or False: Findings from a...
12/14/2021
Journal of Clinical Pathways
Quiz
Quiz: Differences Between Available PARP Inhibitors for Ovarian Cancer
12/08/2021
True or False: There are differences between available PARP inhibitors in the risk of experiencing a clinical event of interest, likelihood of dose modifications, ability to receive continuous therapy, health care resource utilization, and...
True or False: There are differences between available PARP inhibitors in the risk of experiencing a clinical event of interest, likelihood of dose modifications, ability to receive continuous therapy, health care resource utilization, and...
True or False: There are...
12/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Olaparib Maintenance for Ovarian Cancer
10/06/2021
True or False: Olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.
True or False: Olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.
True or False: Olaparib...
10/06/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Olaparib vs Niraparib for the Treatment of Ovarian Cancer
09/24/2021
True or False: Olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
True or False: Olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
True or False: Olaparib is more...
09/24/2021
Journal of Clinical Pathways
Quiz
Quiz: First-Line Maintenance Therapy for Ovarian Cancer
08/05/2021
True or False: First-line maintenance therapy use for ovarian cancer has decreased over time, particularly among patients with biomarker guidance.
True or False: First-line maintenance therapy use for ovarian cancer has decreased over time, particularly among patients with biomarker guidance.
True or False: First-line...
08/05/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of VTE Prophylaxis for Ovarian Cancer
07/27/2021
True or False: Venous thromboembolism prophylaxis with direct oral anticoagulants during neoadjuvant chemotherapy for ovarian cancer is more costly but more effective than no therapy.
True or False: Venous thromboembolism prophylaxis with direct oral anticoagulants during neoadjuvant chemotherapy for ovarian cancer is more costly but more effective than no therapy.
True or False: Venous...
07/27/2021
Journal of Clinical Pathways
Quiz
Quiz: Is First-Line Niraparib Maintenance Cost-Effective for Patients With Advanced Ovarian Cancer?
04/16/2021
04/16/2021
Journal of Clinical Pathways
Quiz
Quiz: How Can We Optimize Genetic Testing for Breast and Ovarian Cancer?
03/17/2021
03/17/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

Overview of the Updated NCCN Guidelines on Ovarian Cancer
Special Report
Overview of the Updated NCCN Guidelines on Ovarian Cancer
06/17/2020
While ovarian cancer is the second most common gynecologic cancer in the United States, behind uterine cancer,1 it is the top gynecologic cancer in mortality.2 In 2020, an estimated 21,750 new cases of ovarian cancer...
While ovarian cancer is the second most common gynecologic cancer in the United States, behind uterine cancer,1 it is the top gynecologic cancer in mortality.2 In 2020, an estimated 21,750 new cases of ovarian cancer...
While...
06/17/2020
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

News
Integrated Clinical Pathway Dashboard Enhances Germline Testing in Patients With Ovarian Cancer
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
News
The Cost-Effectiveness of Prevention Strategies for Individuals Who Carry CSGs for Ovarian Cancer and Breast Cancer
03/18/2024

Grace Taylor

Grace Taylor
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and...
03/18/2024
Journal of Clinical Pathways
News
Individualized Starting Dose of Niraparib in Ovarian Cancer Reduces Hematologic Adverse Event Costs
03/18/2024

Brandon Twyford

Brandon Twyford
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the...
03/18/2024
Journal of Clinical Pathways
News
AI Machine Learning Models Accurately Predict Ovarian Cancer Recurrence and Platinum Sensitivity
03/18/2024
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine...
03/18/2024
Journal of Clinical Pathways
Conference Coverage
Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use